世界の重症筋無力症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myasthenia Gravis Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3985 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、重症筋無力症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、迅速免疫療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・重症筋無力症の市場動向 ・企業の競争状況、市場シェア ・重症筋無力症の種類別市場規模（薬物治療、迅速免疫療法） ・重症筋無力症の用途別市場規模（病院、診療所、その他） ・重症筋無力症の北米市場規模2016-2027（アメリカ、カナダ） ・重症筋無力症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・重症筋無力症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・重症筋無力症の中南米市場規模2016-2027（メキシコ、ブラジル） ・重症筋無力症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Takeda、F. Hoffmann-La Roche、CSL Behring、Grifols、Alexion Pharmaceutical、Avadel Pharmaceuticals、Baxter International、Novartis、Bausch Health、Takeda Pharmaceutical Company） ・結論

Market Analysis and Insights: Global Myasthenia Gravis Market
The global Myasthenia Gravis market size is projected to reach US$ 2212 million by 2026, from US$ 1098.4 million in 2019, at a CAGR of 10.4% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis market.

Global Myasthenia Gravis Scope and Market Size
Myasthenia Gravis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Treatment
Rapid Immunotherapies

Segment by Application
Hospitals
Clinics
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Takeda
F. Hoffmann-La Roche
CSL Behring
Grifols
Alexion Pharmaceutical
Avadel Pharmaceuticals
Baxter International
Novartis
Bausch Health

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myasthenia Gravis Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Treatment
1.2.3 Rapid Immunotherapies
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myasthenia Gravis Market Perspective (2016-2027)
2.2 Myasthenia Gravis Growth Trends by Regions
2.2.1 Myasthenia Gravis Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myasthenia Gravis Historic Market Share by Regions (2016-2021)
2.2.3 Myasthenia Gravis Forecasted Market Size by Regions (2022-2027)
2.3 Myasthenia Gravis Industry Dynamic
2.3.1 Myasthenia Gravis Market Trends
2.3.2 Myasthenia Gravis Market Drivers
2.3.3 Myasthenia Gravis Market Challenges
2.3.4 Myasthenia Gravis Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Players by Revenue
3.1.1 Global Top Myasthenia Gravis Players by Revenue (2016-2021)
3.1.2 Global Myasthenia Gravis Revenue Market Share by Players (2016-2021)
3.2 Global Myasthenia Gravis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Revenue
3.4 Global Myasthenia Gravis Market Concentration Ratio
3.4.1 Global Myasthenia Gravis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Revenue in 2020
3.5 Myasthenia Gravis Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myasthenia Gravis Breakdown Data by Type
4.1 Global Myasthenia Gravis Historic Market Size by Type (2016-2021)
4.2 Global Myasthenia Gravis Forecasted Market Size by Type (2022-2027)

5 Myasthenia Gravis Breakdown Data by Application
5.1 Global Myasthenia Gravis Historic Market Size by Application (2016-2021)
5.2 Global Myasthenia Gravis Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myasthenia Gravis Market Size (2016-2027)
6.2 North America Myasthenia Gravis Market Size by Type
6.2.1 North America Myasthenia Gravis Market Size by Type (2016-2021)
6.2.2 North America Myasthenia Gravis Market Size by Type (2022-2027)
6.2.3 North America Myasthenia Gravis Market Size by Type (2016-2027)
6.3 North America Myasthenia Gravis Market Size by Application
6.3.1 North America Myasthenia Gravis Market Size by Application (2016-2021)
6.3.2 North America Myasthenia Gravis Market Size by Application (2022-2027)
6.3.3 North America Myasthenia Gravis Market Size by Application (2016-2027)
6.4 North America Myasthenia Gravis Market Size by Country
6.4.1 North America Myasthenia Gravis Market Size by Country (2016-2021)
6.4.2 North America Myasthenia Gravis Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Myasthenia Gravis Market Size (2016-2027)
7.2 Europe Myasthenia Gravis Market Size by Type
7.2.1 Europe Myasthenia Gravis Market Size by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis Market Size by Type (2022-2027)
7.2.3 Europe Myasthenia Gravis Market Size by Type (2016-2027)
7.3 Europe Myasthenia Gravis Market Size by Application
7.3.1 Europe Myasthenia Gravis Market Size by Application (2016-2021)
7.3.2 Europe Myasthenia Gravis Market Size by Application (2022-2027)
7.3.3 Europe Myasthenia Gravis Market Size by Application (2016-2027)
7.4 Europe Myasthenia Gravis Market Size by Country
7.4.1 Europe Myasthenia Gravis Market Size by Country (2016-2021)
7.4.2 Europe Myasthenia Gravis Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Market Size (2016-2027)
8.2 Asia-Pacific Myasthenia Gravis Market Size by Type
8.2.1 Asia-Pacific Myasthenia Gravis Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myasthenia Gravis Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myasthenia Gravis Market Size by Type (2016-2027)
8.3 Asia-Pacific Myasthenia Gravis Market Size by Application
8.3.1 Asia-Pacific Myasthenia Gravis Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myasthenia Gravis Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myasthenia Gravis Market Size by Application (2016-2027)
8.4 Asia-Pacific Myasthenia Gravis Market Size by Region
8.4.1 Asia-Pacific Myasthenia Gravis Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myasthenia Gravis Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myasthenia Gravis Market Size (2016-2027)
9.2 Latin America Myasthenia Gravis Market Size by Type
9.2.1 Latin America Myasthenia Gravis Market Size by Type (2016-2021)
9.2.2 Latin America Myasthenia Gravis Market Size by Type (2022-2027)
9.2.3 Latin America Myasthenia Gravis Market Size by Type (2016-2027)
9.3 Latin America Myasthenia Gravis Market Size by Application
9.3.1 Latin America Myasthenia Gravis Market Size by Application (2016-2021)
9.3.2 Latin America Myasthenia Gravis Market Size by Application (2022-2027)
9.3.3 Latin America Myasthenia Gravis Market Size by Application (2016-2027)
9.4 Latin America Myasthenia Gravis Market Size by Country
9.4.1 Latin America Myasthenia Gravis Market Size by Country (2016-2021)
9.4.2 Latin America Myasthenia Gravis Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Market Size (2016-2027)
10.2 Middle East & Africa Myasthenia Gravis Market Size by Type
10.2.1 Middle East & Africa Myasthenia Gravis Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myasthenia Gravis Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myasthenia Gravis Market Size by Type (2016-2027)
10.3 Middle East & Africa Myasthenia Gravis Market Size by Application
10.3.1 Middle East & Africa Myasthenia Gravis Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myasthenia Gravis Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myasthenia Gravis Market Size by Application (2016-2027)
10.4 Middle East & Africa Myasthenia Gravis Market Size by Country
10.4.1 Middle East & Africa Myasthenia Gravis Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myasthenia Gravis Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Myasthenia Gravis Introduction
11.1.4 Takeda Revenue in Myasthenia Gravis Business (2016-2021)
11.1.5 Takeda Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Details
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Myasthenia Gravis Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Myasthenia Gravis Business (2016-2021)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 CSL Behring
11.3.1 CSL Behring Company Details
11.3.2 CSL Behring Business Overview
11.3.3 CSL Behring Myasthenia Gravis Introduction
11.3.4 CSL Behring Revenue in Myasthenia Gravis Business (2016-2021)
11.3.5 CSL Behring Recent Development
11.4 Grifols
11.4.1 Grifols Company Details
11.4.2 Grifols Business Overview
11.4.3 Grifols Myasthenia Gravis Introduction
11.4.4 Grifols Revenue in Myasthenia Gravis Business (2016-2021)
11.4.5 Grifols Recent Development
11.5 Alexion Pharmaceutical
11.5.1 Alexion Pharmaceutical Company Details
11.5.2 Alexion Pharmaceutical Business Overview
11.5.3 Alexion Pharmaceutical Myasthenia Gravis Introduction
11.5.4 Alexion Pharmaceutical Revenue in Myasthenia Gravis Business (2016-2021)
11.5.5 Alexion Pharmaceutical Recent Development
11.6 Avadel Pharmaceuticals
11.6.1 Avadel Pharmaceuticals Company Details
11.6.2 Avadel Pharmaceuticals Business Overview
11.6.3 Avadel Pharmaceuticals Myasthenia Gravis Introduction
11.6.4 Avadel Pharmaceuticals Revenue in Myasthenia Gravis Business (2016-2021)
11.6.5 Avadel Pharmaceuticals Recent Development
11.7 Baxter International
11.7.1 Baxter International Company Details
11.7.2 Baxter International Business Overview
11.7.3 Baxter International Myasthenia Gravis Introduction
11.7.4 Baxter International Revenue in Myasthenia Gravis Business (2016-2021)
11.7.5 Baxter International Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Myasthenia Gravis Introduction
11.8.4 Novartis Revenue in Myasthenia Gravis Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Bausch Health
11.9.1 Bausch Health Company Details
11.9.2 Bausch Health Business Overview
11.9.3 Bausch Health Myasthenia Gravis Introduction
11.9.4 Bausch Health Revenue in Myasthenia Gravis Business (2016-2021)
11.9.5 Bausch Health Recent Development
11.10 Takeda Pharmaceutical Company
11.10.1 Takeda Pharmaceutical Company Company Details
11.10.2 Takeda Pharmaceutical Company Business Overview
11.10.3 Takeda Pharmaceutical Company Myasthenia Gravis Introduction
11.10.4 Takeda Pharmaceutical Company Revenue in Myasthenia Gravis Business (2016-2021)
11.10.5 Takeda Pharmaceutical Company Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myasthenia Gravis Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Treatment
Table 3. Key Players of Rapid Immunotherapies
Table 4. Global Myasthenia Gravis Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Myasthenia Gravis Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Myasthenia Gravis Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Myasthenia Gravis Market Share by Regions (2016-2021)
Table 8. Global Myasthenia Gravis Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Myasthenia Gravis Market Share by Regions (2022-2027)
Table 10. Myasthenia Gravis Market Trends
Table 11. Myasthenia Gravis Market Drivers
Table 12. Myasthenia Gravis Market Challenges
Table 13. Myasthenia Gravis Market Restraints
Table 14. Global Myasthenia Gravis Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Myasthenia Gravis Market Share by Players (2016-2021)
Table 16. Global Top Myasthenia Gravis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis as of 2020)
Table 17. Ranking of Global Top Myasthenia Gravis Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Myasthenia Gravis Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Myasthenia Gravis Product Solution and Service
Table 21. Date of Enter into Myasthenia Gravis Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Myasthenia Gravis Revenue Market Share by Type (2016-2021)
Table 25. Global Myasthenia Gravis Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Myasthenia Gravis Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Myasthenia Gravis Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Myasthenia Gravis Revenue Market Share by Application (2016-2021)
Table 29. Global Myasthenia Gravis Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Myasthenia Gravis Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Myasthenia Gravis Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Myasthenia Gravis Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Myasthenia Gravis Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Myasthenia Gravis Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Myasthenia Gravis Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Myasthenia Gravis Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Myasthenia Gravis Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Myasthenia Gravis Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Myasthenia Gravis Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Myasthenia Gravis Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Myasthenia Gravis Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Myasthenia Gravis Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Myasthenia Gravis Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Myasthenia Gravis Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Myasthenia Gravis Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Myasthenia Gravis Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Myasthenia Gravis Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Myasthenia Gravis Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Myasthenia Gravis Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Myasthenia Gravis Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Myasthenia Gravis Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Myasthenia Gravis Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Myasthenia Gravis Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Myasthenia Gravis Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Myasthenia Gravis Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Myasthenia Gravis Market Size by Country (2022-2027) & (US$ Million)
Table 61. Takeda Company Details
Table 62. Takeda Business Overview
Table 63. Takeda Myasthenia Gravis Product
Table 64. Takeda Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 65. Takeda Recent Development
Table 66. F. Hoffmann-La Roche Company Details
Table 67. F. Hoffmann-La Roche Business Overview
Table 68. F. Hoffmann-La Roche Myasthenia Gravis Product
Table 69. F. Hoffmann-La Roche Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 70. F. Hoffmann-La Roche Recent Development
Table 71. CSL Behring Company Details
Table 72. CSL Behring Business Overview
Table 73. CSL Behring Myasthenia Gravis Product
Table 74. CSL Behring Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 75. CSL Behring Recent Development
Table 76. Grifols Company Details
Table 77. Grifols Business Overview
Table 78. Grifols Myasthenia Gravis Product
Table 79. Grifols Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 80. Grifols Recent Development
Table 81. Alexion Pharmaceutical Company Details
Table 82. Alexion Pharmaceutical Business Overview
Table 83. Alexion Pharmaceutical Myasthenia Gravis Product
Table 84. Alexion Pharmaceutical Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 85. Alexion Pharmaceutical Recent Development
Table 86. Avadel Pharmaceuticals Company Details
Table 87. Avadel Pharmaceuticals Business Overview
Table 88. Avadel Pharmaceuticals Myasthenia Gravis Product
Table 89. Avadel Pharmaceuticals Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 90. Avadel Pharmaceuticals Recent Development
Table 91. Baxter International Company Details
Table 92. Baxter International Business Overview
Table 93. Baxter International Myasthenia Gravis Product
Table 94. Baxter International Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 95. Baxter International Recent Development
Table 96. Novartis Company Details
Table 97. Novartis Business Overview
Table 98. Novartis Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 99. Novartis Recent Development
Table 100. Bausch Health Company Details
Table 101. Bausch Health Business Overview
Table 102. Bausch Health Myasthenia Gravis Product
Table 103. Bausch Health Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 104. Bausch Health Recent Development
Table 105. Takeda Pharmaceutical Company Company Details
Table 106. Takeda Pharmaceutical Company Business Overview
Table 107. Takeda Pharmaceutical Company Myasthenia Gravis Product
Table 108. Takeda Pharmaceutical Company Revenue in Myasthenia Gravis Business (2016-2021) & (US$ Million)
Table 109. Takeda Pharmaceutical Company Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Market Share by Type: 2020 VS 2027
Figure 2. Drug Treatment Features
Figure 3. Rapid Immunotherapies Features
Figure 4. Global Myasthenia Gravis Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Other Case Studies
Figure 8. Myasthenia Gravis Report Years Considered
Figure 9. Global Myasthenia Gravis Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Myasthenia Gravis Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Myasthenia Gravis Market Share by Regions: 2020 VS 2027
Figure 12. Global Myasthenia Gravis Market Share by Regions (2022-2027)
Figure 13. Global Myasthenia Gravis Market Share by Players in 2020
Figure 14. Global Top Myasthenia Gravis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Myasthenia Gravis Revenue in 2020
Figure 16. Global Myasthenia Gravis Revenue Market Share by Type (2016-2021)
Figure 17. Global Myasthenia Gravis Revenue Market Share by Type (2022-2027)
Figure 18. North America Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Myasthenia Gravis Market Share by Type (2016-2027)
Figure 20. North America Myasthenia Gravis Market Share by Application (2016-2027)
Figure 21. North America Myasthenia Gravis Market Share by Country (2016-2027)
Figure 22. United States Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myasthenia Gravis Market Share by Type (2016-2027)
Figure 26. Europe Myasthenia Gravis Market Share by Application (2016-2027)
Figure 27. Europe Myasthenia Gravis Market Share by Country (2016-2027)
Figure 28. Germany Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myasthenia Gravis Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Myasthenia Gravis Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Myasthenia Gravis Market Share by Region (2016-2027)
Figure 38. China Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myasthenia Gravis Market Share by Type (2016-2027)
Figure 46. Latin America Myasthenia Gravis Market Share by Application (2016-2027)
Figure 47. Latin America Myasthenia Gravis Market Share by Country (2016-2027)
Figure 48. Mexico Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myasthenia Gravis Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Myasthenia Gravis Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Myasthenia Gravis Market Share by Country (2016-2027)
Figure 54. Turkey Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Myasthenia Gravis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Takeda Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 58. F. Hoffmann-La Roche Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 59. CSL Behring Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 60. Grifols Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 61. Alexion Pharmaceutical Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 62. Avadel Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 63. Baxter International Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 65. Bausch Health Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 66. Takeda Pharmaceutical Company Revenue Growth Rate in Myasthenia Gravis Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---